首页 › 基金 › SANDS CAPITAL MANAGEMENT, LLC › RARE
SANDS CAPITAL MANAGEMENT, LLC 对 RARE 的持仓历史
ULTRAGENYX PHARMACEUTICAL IN · 医疗保健
SANDS CAPITAL MANAGEMENT, LLC 在 Q2 2026 的 13F 申报中披露持有 RARE(ULTRAGENYX PHARMACEUTICAL IN)3,158,368 股,市值约 US$105.5M,约占其申报组合的 0.39%,在其申报持仓中市值排名第 47 位。 SANDS CAPITAL MANAGEMENT, LLC 最近 12 个申报季度中有 12 个季度披露了 RARE 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
SANDS CAPITAL MANAGEMENT, LLC 对 RARE 的持仓演变
SANDS CAPITAL MANAGEMENT, LLC 于 Q3 2023 首次披露 RARE 持仓:2,577,217 股(约 US$91.9M)。 该持仓在 Q3 2024 达到峰值 5,118,255 股,市值约 US$284.3M。 在 12 次申报中,SANDS CAPITAL MANAGEMENT, LLC 2 次增持、9 次减持、0 次保持不变。 最近一期申报(Q2 2026)显示持股 3,158,368 股、市值约 US$105.5M,环比减持 -56,165 股。。 持仓曾出现大幅变动:Q4 2023 增持约 60% (随后一个季度股价下跌 2%)、Q2 2024 增持约 39% (随后一个季度股价上涨 35%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 2.58M | $91.88M | 新进 |
| Q4 2023 | 4.12M | $196.92M | 增持 |
| Q1 2024 | 3.86M | $180.20M | 减持 |
| Q2 2024 | 5.35M | $220.08M | 增持 |
| Q3 2024 | 5.12M | $284.32M | 减持 |
| Q4 2024 | 4.30M | $180.82M | 减持 |
| Q1 2025 | 4.16M | $150.76M | 减持 |
| Q2 2025 | 3.94M | $143.39M | 减持 |
| Q3 2025 | 3.77M | $113.40M | 减持 |
| Q4 2025 | 3.49M | $80.17M | 减持 |
| Q1 2026 | 3.21M | $67.34M | 减持 |
| Q2 2026 | 3.16M | $105.46M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 RARE 与 13F 数据
RARE(ULTRAGENYX PHARMACEUTICAL IN)属于医疗保健行业。我们追踪的基金中还有 26 只申报持有 RARE,申报仓位最大的包括:RTW INVESTMENTS, LP (US$260.3M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M), Bellevue Group AG (US$66.2M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 RARE 的基金
- RTW INVESTMENTS, LP 7.80M 股 · $260.34M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M 股 · $95.09M · Q2 2026
- Bellevue Group AG 1.98M 股 · $66.20M · Q2 2026
- MPM BioImpact LLC 1.42M 股 · $47.35M · Q2 2026
更多关于 SANDS CAPITAL MANAGEMENT, LLC
常见问题
How long has SANDS CAPITAL MANAGEMENT, LLC held RARE?
SANDS CAPITAL MANAGEMENT, LLC has disclosed RARE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is SANDS CAPITAL MANAGEMENT, LLC's current position in RARE?
As of Q2 2026, SANDS CAPITAL MANAGEMENT, LLC holds 3.16M shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $105.46M, representing 0.39% of its reported portfolio and ranking #47.
Has SANDS CAPITAL MANAGEMENT, LLC been buying or selling RARE?
In the latest 13F filing (Q2 2026), SANDS CAPITAL MANAGEMENT, LLC reduced its position in RARE. The position peaked in Q3 2024 at 5.12M shares.
Which other funds hold RARE?
Other major institutional holders of RARE include RTW INVESTMENTS, LP, FRONTIER CAPITAL MANAGEMENT CO LLC, Bellevue Group AG, among 26 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.